الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 73 |  |  |
| | | from | 73 | | |
Abstract
This randomized controlled clinical trial compared the clinical efficacy of self-adhesive bulk-fill Surefil One with a traditional bulk-fill composite in class II restorations.
Materials and methods: Sixty-four direct Class II composite restorations were categorized into two groups. group I, control group (n=32): cavities were restored by Filtek One Bulk Fill composite with Scotchbond Universal adhesive in self-etch mode, group II, test group (n=32): cavities were restored by Surefil One self-adhesive bulk-fill composite. The study involved a follow-up period of one year, during which restorations were assessed at baseline, six months, and twelve months using FDI criteria. Data analysis was performed using non-parametric tests. A comparison of restoration characteristics was performed utilizing the chi-square test (X2). The significance level was set at 0.05.
Results: Filtek One and Surefil One bulk fill composites revealed clinically acceptable FDI scores over 12-month recalls. Thirty-two patients (64 restorations) were available for all follow-up visits; 100% of the restorations survived. For esthetic properties, Filtek One was far better than Surefil One at all time points. However, in terms of functional and biological properties, both restorations demonstrated comparable performances.
Conclusions: Filtek One bulk fill restorations were superior in terms of surface luster, surface staining, color match, and translucency, but Surefil One restorations performed well and were similar to Filtek One restorations; however, additional advancements and research are needed to obtain better esthetics. Furthermore, longitudinal studies with extended follow-up periods are needed to assess the clinical potential of both materials.
Clinical significance: Both Filtek One and Surefil One met the FDI criteria, with Filtek One demonstrating superior esthetic qualities and similar performance regarding functional and biological criteria. Both innovative bulk-fill materials show potential for clinical use. Trial registered on ClinicalTrials.gov under registration number; NCT06120868:07/11/2023.